CHM
data caveat$9M2mo
Chimeric Therapeutics
Biotech · Cell therapy
CLTX CAR-T cell therapy for glioblastoma
Data HealthTrials2 of 2 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.4M
Dec 2025 4C
Runway
2moCRITICAL
Based on Dec 2025 4C
Market Cap
$9M
Burn Rate
$1.8M/qtr
Dec 2025 4C
Shares Outstanding
44M
Pipeline Assets
2
Latest Insight(1)
18 Mar 20263M Price
CHM.ASX$0.002-20.0% 3M
Low $0.001High $0.003
Pipeline Assets (2)
CDH17 CAR-TGI cancers
PreclinicalCLTX CAR-TGlioblastoma
Phase 1Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
CDH17 CAR-T
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
4 approved drugs269 competitor trialsPhase 2+ · Non-ASX
Gi Cancers20 active trials
4 Ph31 Ph2/38 Ph27 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (4)· 3 upcoming · 1 past
SpeculativeremoveMed1 May 2026
CLTX CAR-T Phase 1 GBM safety data
UpcomingExpectedarrow_upwardHigh31 July 2026
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High96/100
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 4 tracked
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 17% quarterly variation — consistent spend
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
arrow_drop_up
R&D-focused spend — 78% of opex directed to R&D
Completed catalysts
✓Capital raise required— Raised $8.4M (Dec 2025 placement $4.4M + $4.0M convertible note)
113d early
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
2 activeClinicalTrials.gov ↗
Ph1/PHASE2RecruitingEnrollment stale · 707d
CHM-2101 CAR-T cells
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Neuroendocrine Tumors · Colorectal Cancer · Gastric Cancer
18 Years – 85 Years
Primary endpoint Dose-Limiting Toxicity (DLT)
Ph1Active Not RecruitingEnrollment stale · 1051d
CHM-1101 CAR-T cells
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
Glioblastoma Multiforme of Brain
18 Years+
Primary endpoint Dose-limiting toxicity (DLT)